Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13677597 | 0.78 | MAOA (0.46) | MAOAABCG2CA12CA9NPC1 | |
| SCHEMBL28967393 | 0.78 | MAOA (0.56) | MAOAABCG2NPC1MEN1KMT2A | |
| SCHEMBL1102418 | 0.75 | HPGD (0.43) | MAOANPC1MEN1KMT2AKDM4E | |
| SCHEMBL24501838 | 0.74 | CA1 (0.41) | MAOAABCG2CA12CA9NPC1 | |
| SCHEMBL24501824 | 0.73 | TDP1 (0.40) | MAOANPC1MEN1KMT2AKDM4E | |
| SCHEMBL23776007 | 0.71 | TNKS (0.42) | MAOANPC1MEN1KMT2AKDM4E | |
| SCHEMBL13904139 | 0.70 | ALDH1A1 (0.46) | ABCG2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL10431694 | 0.70 | MAOA (0.43) | MAOACA12CA9MEN1KMT2A | |
| SCHEMBL24502111 | 0.70 | TDP1 (0.41) | MAOANPC1MEN1KMT2AKDM4E | |
| SCHEMBL10133341 | 0.70 | MAOA (0.42) | MAOAABCG2CA12CA9NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105683-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | KEEGAN KATHLEEN S | 2010-04-29 | — | — | US | disclosed |
| US-7608618-B2 | Urea or thiourea substituted 1,4-pyrazine compounds useful as anti-cancer agents and for inhibiting Chk1 | ICOS CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105683-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | CHEK1, PCNA, CHEK2 | MAOA 4189/4885ABCG2 2608/4885CA12 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.